Therefore, anti-VEGF agents such as bevacizumab could be included in standard treatment regimens for GBM in order to inhibit angiogenesis and slow tumor growth, while also controlling the development of abnormal peritumoral blood vessels to increase the delivery of systemic chemotherapeutic drugs [23–25]. This evidence concerns the gene VEGFA and neoplasm.